WINTON GROUP Ltd Makes New Investment in Bristol Myers Squibb Company $BMY

WINTON GROUP Ltd bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 18,783 shares of the biopharmaceutical company’s stock, valued at approximately $1,013,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. waypoint wealth counsel acquired a new stake in Bristol Myers Squibb in the fourth quarter worth $1,194,000. Life Cycle Investment Partners Ltd acquired a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $34,406,000. Axxcess Wealth Management LLC increased its position in shares of Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after buying an additional 21,196 shares in the last quarter. M&G PLC raised its stake in Bristol Myers Squibb by 1.4% during the 3rd quarter. M&G PLC now owns 6,885,188 shares of the biopharmaceutical company’s stock worth $309,833,000 after buying an additional 97,063 shares during the period. Finally, Daytona Street Capital LLC bought a new position in Bristol Myers Squibb during the fourth quarter worth about $1,362,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $56.43 on Wednesday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The stock has a market capitalization of $115.23 billion, a P/E ratio of 15.85, a P/E/G ratio of 0.16 and a beta of 0.24. The company has a 50 day moving average of $57.98 and a 200-day moving average of $56.73.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. HSBC boosted their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. Piper Sandler restated an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Finally, Barclays began coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price target on the stock. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $61.31.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.